Research Article
Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
Figure 1
Enrichment and summary plots of the immune-related signatures in TCGA. Enrichment plots of (a) CD8+ cell signature, (b) dendritic cell signature, and (c) Th1 signature in TCGA pooled cohort, all cell signatures of the PDL2-high group were mostly enriched. (d, e) Summary plots of cell signatures with enrichment NES and values in each tumor type, except for the Th1 signature enrichment in the PDL2-low group of THYM, all results are consistent with the results of TCGA pooled cohort. (g–i) Enrichment plots with IFN-γ signatures in TCGA pooled cohort, all IFN-γ signatures were enriched in the PDL2-high group. (j–l) Summary plots of IFN-γ signatures with enrichment NES and value in each tumor type, all IFN-γ signatures were enriched in the PDL2-high group.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |
(j) |
(k) |
(l) |